Raia Drogasil S.A. Gross Profit

The latest gross profit for RADLY is $13B as of June 2026. That compares with $12B in the prior-year period — up 4.0% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Raia Drogasil S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, RADLY's gross profit moved from $12B to $13B — a 4.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Raia Drogasil S.A.'s operating scale or balance-sheet position.

Against Healthcare companies, RADLY currently prints $13B for gross profit, while the sector average sits near $67B. That is roughly 81.2% below the sector mean. Large gaps often invite a closer look at Raia Drogasil S.A.'s growth, margins, and balance sheet.

A gross profit figure of $13B for RADLY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting RADLY's gross profit ($13B), review year-over-year change from $12B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.